In a sign of weak demand, Omrix Biopharmaceuticals, a company that develops biosurgical bleeding control and passive immunotherapy products, priced 3.4 million shares at $10, which is well below its original $15 to $17 range. UBS Investment Bank, CIBC World Markets, Leerink Swann & Co. and Oppenheimer underwrote the deal. Expect the stock to begin trading on the NASDAQ this morning under the symbol OMRI.
